Hyderabad: Transgene Biotek Ltd has said that it has entered into an agreement to acquire Marillion Pharmaceuticals Inc, a US Oncology Biopharmaceuticals company based in Exton, Pennsylvania, in an all-share deal.
The Director of the Hyderabad-based Transgene Biotek, Mr S.S. Marthi, in a statement to the stock exchange, said the transaction would accelerate growth of the company business and broaden scope of drug development.
Marillion Pharmaceuticals, a clinical stage bio-pharmaceuticals company, engaged in development and commercialisation of novel therapeutics in oncology, has presence in the US and manufacturing and licensing partners in the UK and Europe.
New entity
The merger of the two companies and Marillion's products with Transgene's own drug pipeline are expected to create an oncology platform and products for the new merged company. The new entity will be able to play a role in licensing deals with multinational pharmaceutical companies as also develop and commercialise drugs. The revenues are likely to come from Marillion's presence in the US and network of collaborators in Europe. Both the companies see significant expansion of drug development right from the early stage and pre-clinical trials to late stage clinical trials. The merged entity will have a research and business platform and an expanded presence in major markets.
According to the statement, Marillion's portfolio includes three clinical stage products useful in oncology and complements Transgene's portfolio. The latter has earlier out-licensed a manufacturing process to Dr Reddy's Laboratories and its recombinant Hepatitis B vaccine technology to vaccine producer Serum Institute of India.
No comments:
Post a Comment